uniQure BV (QURE) PT Raised to $20 at RBC Capital as 'FDA Leniency Materially De-risks HD'
Tweet Send to a Friend
RBC Capital analyst Luca Issi raised the price target on uniQure BV (NASDAQ: QURE) to $20.00 (from $14.00) while maintaining ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
